Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

Minimal disease activity (MDA) was more likely in people with psoriatic arthritis (PsA) when they initiated a disease-modifying anti-rheumatic drug (DMARD) earlier rather than later. That's according ...

Please provide your email address to receive an email when new articles are posted on . Sustained DMARD-free remission “does not seem attainable” for patients with RA requiring biological DMARDs, but ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...

In their "Impact of delay of treatment with disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis: The CorEvitas psoriatic arthritis/spondyloarthritis registry," published in ACR Open ...

Relapse occurred in over half of patients with juvenile idiopathic arthritis (JIA) within a year of stopping biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) treatment after ...

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...